INTRODUCTION
============

Grade IV astrocytoma, or glioblastoma multiforme (GBM), is a primary brain cancer displaying infiltrative growth properties that are tightly coupled to the vasculature ([@B15]). For example, stem-like GBM cells home to perivascular niches ([@B6]; [@B17]), and invasive GBM cells commonly disperse through the brain microenvironment via extracellular matrix (ECM)--rich vascular basement membranes ([@B43]). Antiangiogenesis compounds that target the vascular endothelial growth factor pathway improve progression-free survival; however, in many patients these benefits are often transient due to invasive cells forming satellite lesions that display resistance to most second-line therapies ([@B10]).

GBM cell invasion is influenced by a milieu of extrinsic cues, including growth factors and ECM proteins within the brain micro­environment ([@B11]; [@B18]). Most mammalian cells adhere to ECM proteins via integrins, a family of heterodimeric cell surface receptors consisting of α and β subunits ([@B21]; [@B8]). Various integrins, their ECM protein ligands, and intracellular signaling effectors play important roles in brain development and physiology ([@B38]; [@B34]), as well as cancer ([@B20]; [@B23]; [@B52]; [@B29]). In particular, integrin αvβ8 is highly expressed in neural progenitor cells of the embryonic and postnatal brain ([@B37], [@B36]; [@B39]; [@B40]). Cell type--specific ablation of αv or β8 integrin genes in neural cells causes CNS-specific angiogenesis phenotypes ([@B36]; [@B48]; [@B16]; [@B2]) that are very similar to those that develop in GBM. αvβ8 integrin is also expressed in GBM cells ([@B50]), and in preclinical models of GBM, αvβ8 integrin can suppress tumor angiogenesis via activation of ECM-bound latent transforming growth factor βs (TGFβs; [@B55], [@B56]). Impaired integrin-mediated latent TGFβ activation leads to defective TGFβ receptor signaling in endothelial cells, causing developmental vascular pathologies resembling those in GBM ([@B16]; [@B44]).

Here we report that αvβ8 integrin drives GBM cell invasion via associations with the intracellular signaling effector Rho-GDP dissociation inhibitor 1 (RhoGDI1). The αvβ8 integrin--RhoGDI1 protein complexes control activation of Rho GTPases in invasive GBM cells, with cells lacking these protein complexes displaying diminished invasiveness due to elevated levels of GTP-bound Rac1 and Cdc42. These data reveal that αvβ8 integrin and RhoGDI1 spatially regulate patterns of GTPase activation to promote tumor cell invasion and suggest that components of this signaling axis may be therapeutic targets for inhibiting invasive GBM cell growth.

RESULTS
=======

During our prior analysis of αvβ8 integrin in GBM-induced angiogenesis, we found that LN229 and SNB19 human GBM cells, which display invasive growth behaviors in vivo, express robust levels of αvβ8 integrin proteins ([@B56]). To further investigate functions for αvβ8 integrin in GBM growth and invasion, we targeted β8 integrin gene (ITGB8) expression by RNA interference (RNAi) using the genetically engineered pLB lentivirus, which contains a U6 promoter that drives expression of short hairpin RNAs (shRNAs) and a cytomegalovirus (CMV) promoter driving green fluorescent protein (GFP) expression ([@B26]). LN229 or SNB19 cells were infected with lentiviruses expressing shRNAs targeting β8 integrin or nontargeting (scrambled) shRNA sequences, and 72--96 h later cells were sorted based on GFP expression. In addition, we analyzed wild-type and β8^−*/*−^ murine astroglial progenitors that were transformed with oncogenes targeting pathways commonly altered in GBM ([@B53]; [@B55]). As shown in [Figure 1, A](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}, in comparison to human GBM cells expressing scrambled shRNAs, a significant reduction in β8 integrin protein expression was detected in GBM cells expressing β8 shRNAs. Integrin protein was completely absent from β8^−*/*−^ -transformed astrocytes owing to gene ablation ([Figure 1E](#F1){ref-type="fig"}). Next we analyzed roles for αvβ8 integrin in tumor cell invasion using three-dimensional Matrigel assays. As shown in [Figure 1, B](#F1){ref-type="fig"} and [D](#F1){ref-type="fig"}, human GBM cells expressing β8 shRNAs displayed significantly reduced invasiveness. Two other lentiviral-delivered shRNAs targeting different regions of ITGB8 also resulted in diminished integrin expression and LN229 cell invasion defects (Supplemental Figure S1). The β8^−*/*−^-transformed mouse astroglial progenitors also showed invasion defects ([Figure 1F](#F1){ref-type="fig"}). Similarly, β8^−*/*−^ primary mouse astrocytes displayed defective invasion in vitro (Supplemental Figure S2). We detected reduced surface expression of αvβ8 integrin protein in GBM cells expressing β8 shRNAs and a complete loss of αvβ8 integrin protein in β8^−*/*−^-transformed astroglial progenitors (Supplemental Figure S3). Silencing β8 integrin did not result in abnormal dimerization between αv integrin and other β integrin subunits (Supplemental Figure S3), similar to our previous reports ([@B55], [@B56]).

![β8 integrin drives GBM cell invasion in vitro. Human LN229 cells (A), SNB19 cells (C), and transformed mouse astrocytes (E) express robust levels of β8 integrin protein. Cells genetically null for β8 integrin or expressing β8 integrin shRNAs show diminished integrin protein expression. LN229 cells (B), SNB19 cells (D), and transformed mouse astrocytes (F) expressing diminished β8 integrin proteins display significantly reduced invasiveness; \**p* \< 0.005.](474fig1){#F1}

To analyze functions for β8 integrin in invasive GBM growth in vivo, we stereotactically injected LN229 cells stably expressing scrambled shRNAs or β8 shRNAs (β8 sh-1) into the striatum of NCR-nu/nu mice. Six different mice (*n* = 6) were injected per cell type, and all animals were killed 6 wk later to compare integrin-dependent tumor growth. As shown in [Figure 2A](#F2){ref-type="fig"}, all LN229 tumors expressing scrambled shRNAs revealed focal, periventricular lesions that displayed infiltrative growth patterns. All intracranial tumors derived from LN229 cells expressing β8 shRNAs were larger and nearly filled the injected hemisphere. Quantitation of tumor volumes by measuring the largest cross-sectional areas in hematoxylin and eosin (H&E)--stained slides revealed 10-fold larger sizes of tumors expressing β8 shRNAs in comparison to nontargeting shRNAs ([Figure 2B](#F2){ref-type="fig"}). H&E staining and anti-GFP immunofluorescence revealed that LN229 cells expressing nontargeting shRNAs displayed diffuse perivascular growth patterns, whereas tumor cells expressing β8 shRNAs showed minimal invasion into the surrounding brain parenchyma and displayed well-defined margins ([Figure 2, C](#F2){ref-type="fig"} and [D](#F2){ref-type="fig"}). Integrin-dependent differences in invasive growth were not due to differential tumor cell proliferation in vivo, since staining brain sections with anti-Ki67 antibodies revealed similar immunoreactivity in tumor cells expressing scrambled shRNAs or β8 shRNAs (Supplemental Figure 4, A and B). Furthermore, in comparison to LN229 cells expressing scrambled shRNAs, cells expressing β8 shRNAs did not display obvious differences in adherent growth in vitro (Supplemental Figure S4C). It is likely that the integrin-dependent differences in tumors volumes are due, in part, to more robust intratumoral angiogenesis and vascular permeability, as we reported previously ([@B55], [@B56]).

![β8 integrin is essential for GBM cell invasion in vivo. (A) Coronal sections from LN229 tumors expressing scrambled shRNAs (top) or β8 shRNAs (bottom) were analyzed by H&E staining. Mice (*n* = 6 per cell type) were injected with GBM cells. Representative images are shown. Scale bars, 2 mm. (B) Quantitation of tumor volumes, as determined by measuring cross-sectional areas of H&E--stained sections. LN229 cells expressing β8 shRNAs generate significantly larger tumors. Sections from six different tumors per cell type were analyzed; *p* \< 0.001. (C) High magnification H&E--stained images from boxed areas in A. Coronal sections through LN229 tumors expressing scrambled shRNAs (top) or β8 shRNAs (bottom). Scale bars, 200 μm. (D) LN229 tumors expressing scrambled shRNAs (top) or β8 shRNAs (bottom) were immunofluorescently labeled with anti-GFP antibodies (green). Note that LN229 cells expressing scrambled shRNAs display robust patterns of perivascular invasion, whereas tumor cells expressing β8 shRNAs display diminished invasiveness. Scale bars, 100 μm.](474fig2){#F2}

Members of the Rho GTPase protein family control cytoskeletal dynamics and play important roles in regulating cell polarity and motility ([@B13]; [Figure 3A](#F3){ref-type="fig"}), leading us to hypothesize that abnormal Rho GTPase activation might underlie the β8 integrin--dependent GBM cell invasion defects. Therefore we analyzed levels of GTP-bound Rho proteins after transient ITGB8 silencing ([Figure 3B](#F3){ref-type="fig"}). In addition, levels of phosphorylated p21-activated kinase (Pak1), which undergoes autophosphorylation upon association with GTP-bound Rho proteins ([@B1]; [@B62]), were quantified. As shown in [Figure 3C](#F3){ref-type="fig"}, elevated levels of phosphorylated Pak1 were detected in GBM cells expressing β8 small interfering RNAs (siRNAs). Lentiviral-delivered shRNAs targeting ITGB8 also showed elevated levels of Pak1 phosphorylation (Supplemental Figure S1). Increased levels of GTP-bound Rac1 and Cdc42, but not RhoA, were also evident in LN229 cells expressing diminished levels of β8 integrin ([Figure 3C](#F3){ref-type="fig"}). Transformed mouse astrocytes genetically null for β8 integrin also displayed increased levels of phosphorylated Pak1, as well as of GTP-bound Rac1 and Cdc42 proteins (Supplemental Figure S5). Reexpression of β8 integrin in β8^−*/*−^ cells resulted in reduced Rac1 and Pak1 activation and significant rescue of invasive cell behaviors (Supplemental Figure S5). Furthermore, tumors derived from LN229 cells expressing β8 shRNAs showed increased levels of phosphorylated Pak1 in situ ([Figure 3, D](#F3){ref-type="fig"} and [E](#F3){ref-type="fig"}).

![β8 integrin suppresses Rac1 and Cdc42 activation in GBM cells. (A) Schematic model for regulation of Rho GTPase and Pak1 activation by extracellular cues. (B) Lysates from LN229 cells expressing scrambled siRNAs or siRNAs targeting β8 integrin were immunoblotted for β8 integrin or actin. (C) Integrin-dependent levels of phosphorylated-Pak1 or GTP-bound Rac1, Cdc42, and RhoA were analyzed in LN229 cell lysates. Phosphorylated Pak1 levels are increased after integrin silencing. Similarly, elevated levels of GTP-bound Rac1 and Cdc42, but not RhoA, were detected in cells expressing diminished levels of β8 integrin. (D, E) Intracranial tumors generated from LN229 cells expressing scrambled shRNAs (D) or β8 shRNAs (E) were analyzed by double immunofluorescence using anti--phospho-Pak1 (red) and anti-GFP (green) antibodies. At least three different sections from four different tumors were analyzed per cell type, with representative images shown. Note the elevated levels of phosphorylated Pak1 in tumor cells expressing β8 shRNAs. Scale bars, 100 μm.](474fig3){#F3}

The increased levels of GTP-bound Rho proteins in cells expressing diminished β8 integrin suggested that Rho hyperactivation contributed to defects in invasion. Therefore we expressed yellow fluorescent protein (YFP)-tagged and constitutively active Rac1 variant (Q61L) in LN229 cells ([Figure 4A](#F4){ref-type="fig"}) and then analyzed cell morphology and invasiveness in vitro. As shown in [Figure 4B](#F4){ref-type="fig"}, in comparison to the elongated morphologies of LN229 cells expressing YFP alone, cells expressing Rac1-Q61L showed flattened morphologies. Three-dimensional Matrigel assays revealed diminished invasive capacities in cells expressing Rac1-Q61L ([Figure 4C](#F4){ref-type="fig"}).

![Rac1 hyperactivation or RhoGDI1 inactivation leads to impaired GBM cell invasion. (A) Lysates from LN229 cells expressing YFP or YFP-tagged Q61L-Rac1 were immunoblotted with anti-Rac1 (left) or anti-GFP (right) antibodies, revealing similar levels of expression. (B) Images of LN229 cells expressing YFP (left) or YFP-tagged Q61L-Rac1 (right). Note the flattened morphologies of cells expressing Q61L-Rac1 (arrows). Scale bar, 60 μm. (C) Quantitation of three-dimensional invasive capacities of LN229 cells expressing YFP or YFP-Q61L-Rac1; \**p* \< 0.05. (D) SNB19 and LN229 cells expressing scrambled shRNAs or β8 shRNAs were analyzed for endogenous RhoGDI1 and RhoGDI2 protein expression. Levels of RhoGDI proteins are not altered in cells expressing β8 shRNAs. (E) LN229 cells transfected with plasmids expressing GFP or GFP-tagged RhoGDI1 were lysed and immunoprecipitated with anti-GFP monoclonal antibodies and immunoblotted with anti-β8 integrin antibodies (top) or anti-GFP polyclonal antibodies (bottom). Note that β8 integrin and RhoGDI1 proteins coimmunoprecipitate, and these associations are reduced in LN229 cells expressing β8 siRNAs. (F) LN229 cells expressing scrambled siRNAs or siRNAs targeting RhoGDI1 were analyzed for RhoGDI1 protein expression. Silencing RhoGDI1 leads to elevated levels of phosphorylated Pak1 and increased levels of GTP-bound Rac1 and Cdc42. (G) Invasive behavior of LN229 cells expressing nontargeting siRNAs or RhoGD1 siRNAs quantified in invasion assays; \**p* \< 0.05.](474fig4){#F4}

In kidney glomerular cells the cytoplasmic domain of β8 integrin interacts directly with RhoGDI1, leading to release of GDP-bound Rac1 from RhoGDI1 and subsequent Rac1 activation ([@B27]). Therefore we interrogated a role for RhoGDIs in integrin-mediated control of GTPase activation. Robust expression of endogenous RhoGDI1 and RhoGDI2 proteins was detected in LN229 and SNB19 GBM cells, and stably silencing β8 integrin with shRNAs did not affect RhoGDI protein levels ([Figure 4D](#F4){ref-type="fig"}). To analyze associations between β8 integrin and RhoGDI proteins, we transfected LN229 cells with plasmids expressing GFP or GFP-tagged RhoGDI1 or RhoGDI2. Detergent-soluble cell lysates were immunoprecipitated with anti-GFP or anti--β8 integrin antibodies, revealing binding between β8 integrin and RhoGDI1 ([Figure 4E](#F4){ref-type="fig"} and Supplemental Figure S6). Interactions between β8 integrin and RhoGDI2 were not detected by coimmunoprecipitation (unpublished data). To determine whether the β8 integrin--dependent GBM cell--invasive behaviors correlated with abnormal regulation of RhoGDI1, we used siRNAs to silence RhoGDI1 gene expression. LN229 cells expressing diminished levels of RhoGDI1 displayed elevated amounts of phosphorylated Pak1, as well as increased levels of GTP-bound Rac1 and Cdc42 ([Figure 4F](#F4){ref-type="fig"}). We next analyzed RhoGDI1-dependent GBM cell invasion. RhoGDI1 silencing also resulted in significantly reduced LN229 and SNB19 GBM cell invasion in three-dimensional Matrigel assays ([Figure 4G](#F4){ref-type="fig"} and Supplemental Figure S7). These results are consistent with a prior report showing that silencing RhoGDI1 resulted in hyperactivation of Rho proteins and reduced cell motility ([@B4]).

To further explore functional links between αvβ8 integrin and RhoGDI1, we generated a β8 integrin mutant construct consisting of the extracellular and transmembrane domains but containing only 10 amino acids of the cytoplasmic tail. As a control we generated a full-length β8 integrin construct containing all 65 amino acids of the β8 integrin cytoplasmic tail (β8.FL) ([Figure 5A](#F5){ref-type="fig"}). In transfected cells these constructs were expressed on the surface and were distinguishable by molecular weight (Supplemental Figure S8). Unlike β8.FL, β8.Trunc did not coimmunoprecipitate with RhoGDI1 in GBM cells (unpublished data). Furthermore, β8.Trunc protein was not immunoreactive with an antibody recognizing the C-terminal integrin tail but was recognized by an antibody directed against the β8 integrin extracellular domain ([Figure 5B](#F5){ref-type="fig"}). To analyze how uncoupling β8 integrin--RhoGDI1 interactions affects Rho GTPase activation, we forcibly expressed β8.Trunc and β8.FL in β8^−*/*−^-mouse transformed astroglial cells. These β8^−*/*−^ cells display high levels of GTP-bound Rac1 and phosphorylated Pak1 and are poorly invasive ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). As shown in [Figure 5C](#F5){ref-type="fig"}, exogenous expression of β8.FL resulted in decreased Rac1 activation and Pak1 phosphorylation. In contrast, forced expression of β8.Trunc did not significantly alter levels of activated Rac1 but did partially diminish levels of phosphorylated Pak1, suggesting that β8.Trunc retains some signaling capacities via Pak1 that are RhoGDI1 independent. To determine how uncoupling β8 integrin-RhoGDI1 interactions influences invasiveness, we analyzed β8^−*/*−^ cells expressing β8.FL or β8.Trunc proteins in Matrigel invasion assays. β8^−*/*−^ cells expressing β8.FL, but not β8.Trunc, displayed a significant increase in invasive behaviors ([Figure 5D](#F5){ref-type="fig"}). Similarly, invasion defects in LN229 cells expressing siRNAs targeting the endogenous ITGB8 3′ untranslated region were largely rescued after exogenous expression of β8.FL but not β8.Trunc (unpublished data). Collectively these data reveal that protein complexes between β8 integrin and its intracellular signaling effector, RhoGDI1, are essential for balancing Rho GTPase activation and GBM cell invasion.

![Uncoupling β8 integrin--RhoGDI1 interactions leads to enhanced Rac1 activation and diminished GBM cell invasion. (A) Diagram showing αvβ8.FL containing 65 amino acids in the β8 integrin cytoplasmic tail and αvβ8.Trunc containing only 10 amino acids in the β8 integrin tail. (B) β8.FL and β8.Trunc proteins were expressed in HEK-293T cells, and lysates were immunoblotted with antibodies recognizing the β8 integrin cytoplasmic (β8cyto) or extracellular domains (β8ex). (C) Expression of β8.FL in β8^−*/*−^ transformed astroglial progenitor cells reduces Rac1 activation, whereas levels of GTP-bound Rac1 remain high in cells expressing β8.Trunc protein. (D) In contrast to β8.FL, β8.Trunc protein does not ameliorate invasion defects in β8^−*/*−^-transformed cells; \**p*, \*\**p* = 0.05.](474fig5){#F5}

We next extended our analysis of cell culture systems and mouse xenograft models to analyze β8 integrin in human clinical samples. First, mRNA expression levels in normal human brain versus GBM samples were compared using Oncomine to query publicly available databases. As shown in [Figure 6A](#F6){ref-type="fig"}, GBM samples from two different cDNA microarray--based studies showed a significant increase in ITGB8 mRNA expression. In the first study, 27 GBM samples were compared with four normal brain samples, revealing a 2.3-fold increase in ITGB8 expression ([@B5]). In the second study, analysis of 81 GBM samples and 27 normal brain samples detected a 2.6-fold increase in ITGB8 levels ([@B54]). Analysis of a cDNA microarray data set for GBM samples generated from The Cancer Genome Atlas (TCGA; [@B46]) revealed a similar twofold increase (*p* = 2.8 × 10^−6^) in ITGB8 expression in GBM samples versus normal brain tissue. Of interest, a separate TCGA-based analysis of gene expression profiles in GBM identified ITGB8 as a molecular marker for "classic" GBM subtypes ([@B61]).

![High ITGB8 expression in GBM correlates with reduced patient survival. (A) Oncomine summary of two independent transcriptome data sets comparing normal human brain samples to GBM samples. A greater-than-twofold increase in ITGB8 expression was detected in GBM samples as compared with normal brain samples. (B) Two different human brain sections containing neural tissue adjacent to the primary GBM were immunostained with anti--β8 integrin antibodies. Note the low levels of β8 integrin protein expression in the normal human brain. Bottom, a tumor margin revealing β8 integrin protein markedly upregulated in GBM cells. (C) Four different human GBM samples near the tumor core were immunolabeled with anti--β8 integrin antibodies. Note the robust levels of β8 integrin protein in tumor cells, with little if any integrin expression in intratumoral blood vessels (arrows). Scale bars, 200 μm. (D) Kaplan--Meier survival curve comparing human glioma samples with twofold or greater ITGB8 expression (*n* = 114) vs. samples with intermediate levels of ITGB8 expression (*n* = 225). Elevated ITGB8 expression correlates with diminished patient survival; \**p* \< 0.001. Results were generated using the National Cancer Institute REMBRANDT database.](474fig6){#F6}

In addition, we analyzed β8 integrin protein expression in four different GBM samples by immunostaining Formalin-fixed, paraffin-embedded sections with human-specific goat anti--β8 integrin antibodies. As shown in [Figure 6B](#F6){ref-type="fig"}, low levels of β8 integrin protein were detected in "normal" brain regions adjacent to the primary GBM mass, with higher integrin expression in GBM cells in the adjacent tumor. Within the GBM core we detected robust β8 integrin protein expression in tumor cells but not in intratumoral blood vessels ([Figure 6C](#F6){ref-type="fig"}). The goat anti--β8 integrin antibody specificity was confirmed by immunostaining GBM samples with nonspecific control immunoglobulin Gs (Supplemental Figure S9). In addition, analysis of the National Cancer Institute Repository of Molecular Brain Neoplasia Data database (<http://rembrandt.nci.nih.gov>) revealed that astrocytoma samples with a twofold or greater increase in ITGB8 expression (*n* = 114) correlated with diminished patient survival ([Figure 6D](#F6){ref-type="fig"}) as compared with astrocytoma samples with intermediate levels of ITGB8 expression (*n* = 225). Collectively these data reveal that increased β8 integrin expression predicts poor outcome, likely due to enhanced invasive GBM cell growth.

DISCUSSION
==========

In this article we characterized β8 integrin--dependent signaling pathways that drive GBM cell invasion. Our experiments reveal the following novel findings: 1) β8 integrin is highly expressed in human GBM cells, and RNAi-mediated silencing of integrin expression significantly diminishes invasiveness in vitro and in vivo ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}); 2) β8 integrin suppresses Rho GTPase activation in GBM cells, with diminished β8 integrin expression leading to elevated levels of GTP-bound Cdc42 and Rac1 ([Figure 3](#F3){ref-type="fig"}); 3) expression of a hyperactive Rac1 variant or RNAi-mediated silencing of RhoGDI1 in GBM cells leads to diminished invasiveness ([Figure 4](#F4){ref-type="fig"}); 4) uncoupling integrin--RhoGDI1 associations leads to Rac1 hyperactivation and diminished invasiveness ([Figure 5](#F5){ref-type="fig"}); and 5) β8 integrin mRNA and protein are highly expressed in many human GBM samples, with elevated levels of expression correlating with reduced patient survival ([Figure 6](#F6){ref-type="fig"}). Collectively these data reveal for the first time that β8 integrin regulates the activation status of Rho GTPases to promote GBM cell invasion within the brain microenvironment ([Figure 7](#F7){ref-type="fig"}).

![αvβ8 integrin--RhoGDI1 protein complexes regulate Rho GTPase activation and drive GBM cell invasion. (A) αvβ8 integrin is expressed in GBM cells, where it interacts with RhoGDI1 via the β8 cytoplasmic tail. αvβ8 integrin--RhoGDI1 protein complexes recruit GDP-bound Rac1 and Cdc42 to control activation of Rho proteins, thus driving GBM cell polarity and invasion. In addition, αvβ8 integrin likely binds to ECM protein ligands, including latent TGFβs, to regulate intracellular signaling pathways involved in GBM cell invasion. (B) Uncoupling αvβ8 integrin--RhoGDI1 protein complexes by mutating the integrin cytoplasmic tail or silencing β8 integrin or RhoGDI1 gene expression leads to elevated levels of GTP-bound Rho proteins, resulting in diminished GBM cell polarity and invasion.](474fig7){#F7}

The primary amino acid sequence of the β8 integrin cytoplasmic domain shares little homology with other β integrin subunits. For example, the NPXY peptide motif present in most integrin cytoplasmic tails, which facilitates interactions with FERM domain--containing proteins such as talins ([@B25]) and kindlins ([@B33]), is absent in β8 integrin. These differences suggest that β8 integrin activation and/or signaling occur via mechanisms distinct from those used by other integrins. Indeed, our group and others have found that the β8 integrin cytoplasmic tail signals via intracellular proteins that are not commonly associated with other integrins ([@B35]; [@B59]). In the kidney direct interactions between β8 integrin and RhoGDI1 lead to dissociation of Rac1 from RhoGDI1, enabling increased Rac1 activation and suppression of RhoA activation. Integrin-dependent balances between activated (GTP-bound) forms of Rac1 and RhoA normally inhibit mesangial cell differentiation ([@B27]), with β8^−*/*−^ or RhoGDI1^−*/*−^ cells showing elevated levels of active RhoA, diminished levels of active Rac1, and a differentiated myofibroblast-like phenotype. In contrast, our experiments reveal that uncoupling interactions between β8 integrin and RhoGDI1 in GBM cells leads to increased levels of Rac1 and Cdc42 activation and impaired invasion, suggesting GBM cell type--specific roles for β8 integrin in regulating RhoGDI1 functions. Nonetheless, these data support a model ([Figure 7](#F7){ref-type="fig"}) in which β8 integrin enhances the affinity of RhoGDI1 for GDP-bound Rhos, possibly resulting in increased extraction of GDP-bound Rhos from the plasma membrane or decreased delivery from the endoplasmic reticulum to the plasma membrane. The activated Rho proteins in GBM cells expressing β8 shRNAs are quite likely membrane associated, since a prior report demonstrated that silencing RhoGDI1 expression leads to enriched levels of membranous GTP-bound Rho proteins and impaired directional motility ([@B4]).

Other proteins in addition to β8 integrin interact with RhoGDIs to maintain precise levels of GTP-bound Rho proteins ([@B13]). For example, complexes of RhoGDI1, synectin, and syndecan 4 sequester GDP-bound RhoG during endothelial cell growth and migration ([@B9]). During axonal growth the nerve growth factor receptor p75 binds directly to the RhoGDI1 complex to release GDP-bound Rho proteins ([@B64]). In GBM cells semaphorin 5A promotes recruitment of RhoGDI1 to plexin-B3, leading to reduced invasiveness ([@B30]). Associations between β8 integrin and RhoGDI1 may serve to localize RhoGDI1 to membranes, thus stimulating binding of GDP-bound Cdc42 and Rac1 at the invasive front of a tumor cell to limit their activation by growth factors and β1 integrins ([@B7]). Alternatively, β8 integrin--RhoGDI1 associations may occur at the trailing edge, thus facilitating retraction as the cell navigates through the ECM. In addition, integrin adhesion to ECM protein ligands likely influences intracellular signaling. The β8 integrin cytoplasmic tail is dispensable for latent TGFβ activation ([@B42]); hence it remains possible that αvβ8 integrin--mediated TGFβ activation in the ECM regulates intracellular signaling via RhoGDI1 and other effectors. Of interest, genetic interactions between αvβ8 integrin and the guanine nucleotide exchange factor β-Pix are essential for brain development ([@B31]). β-Pix facilitates the exchange of GDP to GTP in Rac1 and binds to phosphorylated Pak1 ([@B57]; [@B1]). Different pools of αvβ8 integrin protein, possibly localized to different membrane domains, may interact with RhoGDI1 versus β-Pix. Alternatively, a multimeric protein complex consisting of αvβ8 integrin, RhoGDI1, β-Pix, and other signaling effectors might control the proper temporal and spatial activation of Rho proteins. Along these lines, in the rescue experiments involving β8.Trunc protein we detected a minor rescue of Pak1 signaling ([Figure 5](#F5){ref-type="fig"}), suggesting that interactions with other effectors in addition to RhoGDI1 might control proinvasive signaling.

Our data showing that integrin regulation of Rho activation promotes GBM cell invasion might have clinical relevance. The invasive behaviors of GBM cells make them resistant to most interventions, with infiltrating cells escaping surgical resection and generating lethal secondary lesions. Furthermore, antivascular therapies such as Avastin/bevacizumab result in only modest improvements in progression-free survival ([@B3]; [@B12]; [@B45]) due to compensation by vascular endothelial growth factor (VEGF)-independent angiogenic pathways, as well as by enhanced GBM cell infiltration ([@B32]; [@B47]; [@B14]; [@B24]; [@B49]). Thus, components of the β8 integrin--RhoGDI1 signaling axis might be therapeutic targets for inhibiting GBM cell invasion during cancer progression and after antivascular therapies. Finally, overexpression of ITGB8 and Rho signaling pathway genes have been reported in peripheral nerve sheath tumors, and silencing these factors diminishes invasiveness ([@B60]). In addition, αvβ8 integrin has been reported to promote invasive cell growth in nonneural cancers; for example, breast cancer cells up-regulate β8 integrin during metastatic dispersal to the lung ([@B28]), and silencing integrin expression leads to diminished metastatic lesions ([@B63]). Hence ITGB8, RhoGDI1, and related signaling components might drive invasive cell growth in cancers outside of the CNS.

MATERIALS AND METHODS
=====================

GBM cell lines and human tumor samples
--------------------------------------

LN229 and SNB19 human GBM cell lines were purchased from the American Type Culture Collection (Manassas, VA). Approval for the use of human specimens was obtained from the Institutional Review Board (IRB) at the University of Texas MD Anderson Cancer Center. The IRB waived the requirement for informed consent for previously collected residual tissues from surgical procedures stripped of unique patient identifiers according to Declaration of Helsinki guidelines. Oncomine (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization of integrin gene expression levels in normal human brain versus GBM samples. REMBRANDT (<http://rembrandt.nci.nih.gov>) was used to generate integrin-dependent patient survival. TCGA-based analysis of ITGB8 expression levels in GBM samples was performed at <http://csbi.ltdk.helsinki.fi/anduril/tcga-gbm> ([@B46]).

Antibodies and immunohistochemistry
-----------------------------------

The following antibodies were purchased from commercial sources: goat anti--β8 integrin (C-19; Santa Cruz Biotechnology, Santa Cruz, CA), rabbit or mouse anti-GFP (Abcam, Cambridge, MA), rabbit anti-actin (Sigma-Aldrich, St. Louis, MO), rabbit anti-Ki67 (Dako, Carpinteria, CA), rabbit anti-Cdc42 and anti-RhoA (Cell Signaling, Beverly, MA), mouse anti-Rac1 and rabbit anti-RhoGDI1 (Millipore, Billerica, MA), rabbit anti-RhoGDI2 (Thermo Scientific, Waltham, MA), and rabbit anti-pPak1 used for immunohistochemistry (Abcam). The anti--phospho-Pak1 antibody used for immunoblotting has been reported previously ([@B51]). The anti--αv integrin and anti-β8 rabbit polyclonal antibodies directed against the integrin cytoplasmic tail have been described elsewhere ([@B35]; [@B22]). Goat anti-β8 antibodies directed against the integrin extracellular domain used for immunohistochemistry (C-19) and immunoprecipitation/immunoblotting (G-17) were purchased from Santa Cruz Biotechnology. Secondary antibodies used for immunofluorescence were all conjugated to Alexa 488 or Alexa 594 (Molecular Probes, Eugene, OR). Horseradish peroxidase (HRP)--conjugated secondary antibodies were purchased from Jackson ImmunoResearch Labs (West Grove, PA).

Formalin-fixed, paraffin-embedded sections were incubated in blocking solution, and then primary antibodies were added. Sections were rinsed three times with phosphate-buffered saline (PBS), blocked with peroxidase solution, and incubated with secondary antibodies conjugated to HRP. Then VIP or DAB chromagens were added to visualize immunoreactivity. LN229 and SNB19 GBM cells were purchased from the American Type Culture Collection and cultured in DMEM/F12 (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and antibiotics. Isolation and transformation of wild-type and β8^−*/*−^ mouse astrocytes has been described previously ([@B55]).

Plasmids, lentiviral vectors, and siRNAs
----------------------------------------

Plasmids expressing GFP-tagged RhoGDI1 and RhoGDI2 have been described elsewhere ([@B41]). The plasmid expressing Q61L-Rac1 tagged at the N-terminus with YFP has been described previously and was purchased from Addgene (Cambridge, MA; [@B19]). Oligonucleotide sequences and detailed methods for generation of shRNAs targeting β8 integrin have been described elsewhere ([@B56]). Viruses were packaged by transfecting 293-FT cells (American Type Culture Collection) with pLB transfer vectors and plasmids encoding gag/pol and VSV-G envelope proteins. Pools of siRNAs targeting human β8 integrin or RhoGDI1 were purchased from Dharmacon (Lafayette, CO). GBM cells were transfected with siRNAs using manufacturers' reagents. Full length (1--769) or truncated (1--714) human ITGB8 cDNAs were amplified by PCR and subcloned into *Eco*RI/*Bam*HI sites of either pcDNA3.1 or the pCDH lentivirus transfer vector (pCDH-CMV-MCS-EF1-copGFP), and DNA cloning was confirmed by sequencing. Full-length human ITGB8 contains 65 amino acids of the cytoplasmic domain, whereas the truncated construct contains only the 10 juxtamembrane amino acids.

Stereotactic injections
-----------------------

All animal procedures were conducted under Institutional Animal Care and Use Committee--approved protocols. NCR-nu/nu male mice (Jackson Laboratory, Bar Harbor, ME) were anesthetized, and a single incision was made from the anterior pole of the skull to the posterior ridge. We targeted the striatum for cell implantation using the following stereotactic coordinates: 1.5 mm rostral, 1.5 mm anterior, and 4 mm below the pial surface. An automated micropump (Stoelting Instruments, Wood Dale, IL) was used to dispense cells in 3 μl of PBS over a 5-min period. Human intracranial tumors were generated by injecting 2 × 10^5^ LN229 GBM cells into the striatum of mice. Animals were monitored for tumor-related neurological deficits, and moribund animals were killed with gaseous CO~2~. Mice were perfused with 4% paraformaldehyde/PBS, and brains were coronally sliced at 1-mm intervals; paraffin-embedded tissues were serially sectioned at 7-μm intervals.

Invasion assays
---------------

We added 5 × 10^4^ cells in serum-free media to the upper chambers of Matrigel invasion Transwell systems with 8-μm pore sizes (BD Biosciences, San Diego, CA). Growth medium containing 10% fetal bovine serum was added to the lower wells, and invasion was quantified after 18--24 h by staining with hematoxylin and counting the number of invasive cells on the underside of the Transwell filter. For determining the invasion index, the average number of invading cells under control conditions (scrambled shRNAs or siRNAs) was set at 1 and then compared with cells expressing targeted shRNAs or siRNAs.

GTPase activation assays
------------------------

GTP-bound Cdc42 and Rac1 were fractionated using glutathione *S*-transferase--tagged p21-binding domain of Pak1 as previously described ([@B58]). Rhotekin conjugated to agarose (Cytoskeleton, Denver, CO) was used for fractionating GTP-bound RhoA. Cells were harvested in Mg^2+^ lysis buffer containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.5, 150 mM NaCl, 1% NP-40, and 10 mM MgCl~2~ containing 1 mM dithiothreitol, 1 mM Na~3~VO~4~, 10 mM NaF, 10 mM β-glycerol phosphate, and EDTA-free protease inhibitors (Roche, Indianapolis, IN). The lysates were incubated with PBD or Rhotekin beads for 20 min at 4°C. After precipitation, the pellets were washed three times with Mg^2+^ lysis buffer and then analyzed by Western blotting to determine levels of active Rac1, Cdc42, or RhoA.

Statistical analyses
--------------------

Student\'s *t* test was performed to determine statistically significant differences between groups. The Wilcoxon rank sum test was used for analysis of Kaplan--Meier survival results. Excel (Microsoft, Redmond, WA) was used to calculate statistics.
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:   extracellular matrix
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